HOAC Virtual: New perspectives on glaucoma: understanding the mechanisms underlying vision loss



Where: Online

Glaucoma is the world's leading cause of irreversible blindness, affecting approximately 500,000 people in England and Wales, and 80 million people worldwide. With an ageing population, prevalence of glaucoma is rising. Visual field loss is the only functional biomarker for glaucoma, and perimetry is the only way to measure the effect of glaucoma on how well patients see. However, the current standard perimetry test was designed 40 years ago, before the pathophysiology of glaucoma was understood. Arbitrarily designed stimuli (imported from its predecessor, Goldmann kinetic perimetry, when tests became more automated) and high associated measurement variability make it difficult to identify glaucomatous loss in the first instance and detect signs of progression.

In this webinar, we will discuss ways in which perimetry can be improved for a more accurate and precise measurement and interpretation of glaucomatous visual field loss, based on new evidence for changes in the visual pathway in glaucoma. We will also discuss some common pitfalls and misconceptions around alternative visual field tests.

This session is part of HOAC Virtual 2021, a one day event providing education for those working in a hospital environment. For more information on the other sessions please click here.


This webinar is approved for one interactive CET point (O, TO, DO).

To be eligible for the CET you must attend for the duration of the session. We recommend you join the session at least five minutes before the webinar is due to begin.

13:30 - 14:30

  • New perspectives on glaucoma: understanding the mechanisms underlying vision loss

Learning objectives


6.1.8 Be aware of the latest evidence for changes that occur in the visual pathway in glaucoma

3.1.5 Be able to optimise visual field testing when investigating glaucoma

Therapeutic prescriber

2.1.2 Be able to optimise visual field assessment for detecting and monitoring cases of glaucoma to inform management decisions

Dispensing optician

3.1.5 Be aware of the test strategies for the investigation of glaucoma

8.1.5 Be aware of the latest evidence for changes that occur in the visual pathway in glaucoma

Therapeutic Prescribers 



Ocular disease logo

Ocular Disease



Ocular examination logo

Ocular Examination



Therapeutic prescriber

Options logoOptions



Dispensing optician

Ocular examination logo

Ocular Examination

Dr Tony Redmond

Dr Tony Redmond is a senior lecturer in the School of Optometry and Vision Sciences, Cardiff University. His primary area of research interest is in visual psychophysics, with a particular emphasis on understanding neural changes in disease through measurements of specific attributes of visual function, and translation of basic science to the clinical setting. He regularly publishes in high-profile peer-reviewed scientific journals and has presented original research in many national and international conferences. He is an editorial board member for the Optometry in Practice and Current Eye Research journals. Tony has also worked as a specialist optometrist in glaucoma, refraction, and contact lens clinics at Moorfields Eye Hospital, London.


Optelec logoOur objective is simple: Improving the quality of life of those with sight loss – reaching out with simple and effective solutions. We aim to help anyone with a sight difficulty, whether they are blind or have a degree of vision impairment, by offering simple to use and intuitive solutions. We provide assistive technology that ranges from optical magnifiers to full text to speech devices.

Our products are designed to help make the most of life: to allow staying in touch with friends and relatives, participating and succeeding in education and the workplace, and continuing to enjoy hobbies. We have four marketing leading brands that we offer; Optelec, Enhanced Vision, Freedom Scientific and Schweizer.

No7 Bio


For over 40 years, No7 Contact Lenses have driven the future of specialist contact lenses. In collaboration with industry-leading global partners, we've developed products and services that can change lives and help businesses differentiate and thrive.

With a proud history of innovation, we are inspired by a drive to give every patient the sense of health and well-being they deserve. In the 80's we introduced CNC lathing technology. By the '90s, we had developed our first aspheric GP lens. The '00s saw us launch ortho-k, hybrid and scleral designs, and more recently, we've rolled out an educational website dedicated to ECPs who fit irregular corneas.

Now established as the UK's leading manufacturer of specialist lenses, No7 looks toward an exciting future. Our experienced and knowledgeable team will continue to explore fresh opportunities, working in partnership with eye care practitioners to give every patient the chance of a happy life with healthy vision.


Menicon logoMenicon is one of the world’s largest suppliers of contact lenses. Established in 1951 in Japan, it has a presence in more than 80 countries and this year is proudly celebrating its 70th Anniversary.

The UK headquarters in Northampton is dedicated to contact lens design and manufacture from start to finish.

In 2009, the long-established British firm of David Thomas Contact Lenses was acquired, which some years earlier had taken over Nova Contact Lenses, manufacturers of Rose K, which is the most widely prescribed brand of irregular cornea lenses worldwide.

Menicon’s highest priority is eye health, using precision craftsmanship to help people see life in wonderful detail and combining the traditional values of quality, expertise and service with innovative lens design.